September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Brahmer Highlights Immunotherapies in the Pipeline for NSCLC
January 29th 2019During a presentation at the <em>16th Annual </em>Winter Lung Cancer Conference, Julie R. Brahmer, MD, MSc shed light on some of the immunotherapy treatment options that could be entering the lung cancer pipeline over the next 5 years.
Read More
Garon Emphasizes Impact of Durvalumab Success in Stage III NSCLC
January 29th 2019Edward B. Garon, MD, discusses the newer role of immunotherapy in the treatment of patients with unresectable stage III NSCLC with the approval of durvalumab in this setting for patients whose disease has not progressed following concurrent chemoradiation.
Read More
Using EGFR-Targeted Activity to Distinguish Between TKIs in NSCLC
January 28th 2019During a presentation at the 16th Annual Winter Lung Conference, Gregory J. Riely, MD, PhD, discusses how oncologists can differentiate between the many EGFR TKIs available for patients with <em>EGFR</em>-mutant non–small cell lung cancer.
Read More
BMS Withdraws Nivolumab/Ipilimumab Application in TMB-High NSCLC
January 26th 2019Bristol-Myers Squibb has announced its decision to withdraw a supplemental biologics license application currently with the FDA seeking frontline approval for the combination of nivolumab and ipilimumab for patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.
Read More
Atezolizumab/Bevacizumab Combo Shows Potential in EGFR-Mutant NSCLC
January 25th 2019Both overall survival and progression-free survival were improved in patients with <em>EGFR</em>-mutant nonsquamous cell lung cancer who were treated with the combination of atezolizumab, bevacizumab, and chemotherapy compared with bevacizumab plus chemotherapy, according to an exploratory analysis of the IMpower150 study.
Read More
Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC
January 25th 2019Patients who continued receiving osimertinib after their non–small cell lung cancer had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from The University of Texas MD Anderson Cancer Center and the Moffitt Cancer Center and Research Institute.
Read More
Differences in Treatment Facilities, Histology Account for Survival Disparities in NSCLC
January 25th 2019A retrospective analysis of survival data from patients with metastatic non–small cell lung cancer showed that patients who received treatment at academic centers had better survival rates than those treated at community-based centers, and this disparity was more pronounced when patients were stratified by histology.
Read More
FDA Accepts sBLA for Frontline Atezolizumab Triplet in Nonsquamous NSCLC
January 17th 2019A supplemental biologics license application submitted to the FDA for atezolizumab, carboplatin, and nab-paclitaxel has been accepted. The application, based on findings from the phase III IMpower130 trial, is seeking the agent's approval for patients with metastatic nonsquamous non–small cell lung cancer.
Read More
Broad-Panel NGS Benefits Metastatic NSCLC
January 11th 2019Increasing clinical relevance of less common gene signatures and alterations is leading to a benefit from broad-panel next-generation sequencing testing for patients with metastatic non–small cell lung cancer, according to an expert at Memorial Sloan Kettering Cancer Center.
Read More
Cancer Death Rates on the Decline, 2019 Cancer Stats Report Shows
January 10th 2019Due to the significant decline in smoking and an increase in advances for early cancer detection and screening, the cancer death rate has declined 27% in the United States from 1991 to 2016, according to the American Cancer Society’s annual report on cancer rates.
Read More